Drug Profile


Alternative Names: PSGL-1Ig; Recombinant P-selectin glycoprotein ligand-1 fusion protein; rPSGL-Ig

Latest Information Update: 11 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Wyeth; Ys Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Antithrombotics; Recombinant fusion proteins
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Deep vein thrombosis; Delayed graft function; Inflammation; Myocardial infarction; Ocular inflammation; Renal transplant rejection; Reperfusion injury; Sickle cell anaemia; Thrombosis

Most Recent Events

  • 11 Sep 2015 Discontinued - Phase-I/II for Delayed graft function (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued - Phase-II for Reperfusion injury (Prevention) in USA (IV)
  • 11 Sep 2015 Discontinued for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top